1.2. Pediatrics
Tiotropium is FDA-approved for asthma maintenance therapy in pediatric patients 6-17 years of age. Safety and efficacy of inhaled aclidinium, ipratropium, umeclidinium, and glycopyrrolate in children have not been established, as COPD does not usually develop in the pediatric population. Maximum recommended inhaled anticholinergic pediatric dosages are summarized in Table 3. Dosages exceeding these recommendations will be reviewed.
Drug Name | Dosage Form/Strength | Treatment Indication | Patient Age/Maximum Recommended Dosage |
---|---|---|---|
tiotropium (Spiriva® Respimat®) | inhalation cartridge (1.25 mcg/ actuation) | Asthma | 6-17 years of age: 2 inhalations of 1.25 mcg/ actuation once daily (total dose = 2.5 mcg) |